Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age

alan, murat; KOÇ, Altuğ; Sancı, Muzaffer; ÖZDEMİR, Taha Reşid

Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age

Taha Reşid ÖZDEMİR, (Sağlık Bakanlığı)

Murat ALAN, (Sağlık Bakanlığı)

Muzaffer SANCI, (Sağlık Bakanlığı)

Altuğ KOÇ (Sağlık Bakanlığı)

Balkan Medical Journal

1 0

Yıl: 2019 Cilt: 36 Sayı: 1 Sayfa Aralığı: 37 - 42 Metin Dili: İngilizce İndeks Tarihi: 16-01-2020

Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age

Öz:

Background: Lynch syndrome is an inherited cancer disorder that causes an increased lifetime risk of various types of cancers. Endometrial cancer is the most common extracolonic cancer in Lynch syndrome. Guidelines recommend that patients with endometrial cancer younger than 50 years of age should be evaluated for Lynch syndrome. Molecular analysis of the mismatch repair genes and EPCAM gene is required for a definitive diagnosis of Lynch syndrome.Aims: To report the mutation analysis of mismatch repair genes using targeted next-generation sequencing in endometrial cancer diagnosed patients <50 years of age.Study Design: Retrospective cross-sectional study.Methods: Seventy-nine endometrial cancer diagnosed patients <50 years of age underwent genetic counseling. They were selected among 1094 consecutive endometrial cancer patients between 2006 and 2017. Molecular analysis of MLH1, MSH2, and MSH6 genes was performed in 79 patients by using next-generation sequencing. Deletion/duplication analysis of mismatch repair genes and EPCAM gene was also performed in 79 patients by using the multiplex ligation-dependent probe amplification method.Results: Germline testing of mismatch repair genes was performed in 79 endometrial cancer patients. Lynch syndrome was confirmed in 4 patients (5%; 4/79). A total of 14 variants (6 in MSH2, 5 in MLH1, 3 in MSH6 genes) were found in 14 patients. Four variants were assessed as pathogenic/likely pathogenic, and 10 variants were assessed as variants of uncertain significance.Conclusion: Lynch syndrome should be investigated in patients diagnosed with endometrial cancer that are less than 50 years of age due to the increased lifetime risk of developing cancer.

Anahtar Kelime:

Konular: Tıbbi İnformatik Tıbbi Araştırmalar Deneysel Genel ve Dahili Tıp Klinik Nöroloji Temel Sağlık Hizmetleri Sağlık Bilimleri ve Hizmetleri Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Win AK, Jenkins MA, Dowty JG, Antoniou AC, Lee A, Giles GG, et al. Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2017;26:404-12.
Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015;136:3-7.
Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011;29:2247-52.
Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 2015;17:70-87.
Kastrinos F, Uno H, Ukaegbu C, Alvero C, McFarland A, Yurgelun MB, et al. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol 2017;35:2165-72. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative Genomics Viewer. Nat Biotechnol 2011;29:24-6.
Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178-92.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants lodged on the InSiGHT locus-specific database. Nat Genet 2014;46:107-15.
Schwarz JM, Cooper DN, Schuelke M, Seelow D. Mutation Taster 2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361-2.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-81.
Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009;37:67.
Hutter P, Couturier A, Membrez V, Joris F, Sappino AP, Chappuis PO. Excess of hMLH1 germline mutations in Swiss families with hereditary non-polyposis colorectal cancer. Int J Cancer 1998;78:680-4.
Chong G, Jarry J, Marcus V, Thiffault I, Winocour S, Monczak Y, et al. High frequency of exon deletions and putative founder effects in French Canadian Lynch syndrome families. Hum Mutat 2009;30:797-812.
Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7.
Clarke BA, Cooper K. Identifying Lynch syndrome in patients with endometrial carcinoma: shortcomings of morphologic and clinical schemas. Adv Anat Pathol 2012;19:231-8.
Berends MJ, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJ, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003;21:4364-70.
Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 2003;100:5908-13.
Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Järvelä I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol 2005;23:4609-16.
Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, et al. Prospective Determination of Prevalence of Lynch Syndrome in Young Women with Endometrial Cancer. J Clin Oncol 2007;25:5158-64.
Anagnostopoulos A, McKay VH, Cooper I, Campbell F, Greenhalgh L, Kirwan J. Identifying Lynch Syndrome in Women Presenting With Endometrial Carcinoma Under the Age of 50 Years. Int J Gynecol Cancer 2017;27:931-7. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 2. 2012: Accessed November 1, 2013. http://www.nccn.org/professionals/physician_gls/PDF/colorectal_screening. pdf.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014;109:1159-79.
Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015;110:223-62.
Herzig DO, Buie WD, Weiser MR, You YN, Rafferty JF, Feingold D, et al. Clinical Practice Guidelines for the Surgical Treatment of Patients With Lynch Syndrome. Dis Colon Rectum 2017;60:137-43.

APA	ÖZDEMİR T, alan m, Sancı M, KOÇ A (2019). Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. , 37 - 42.
Chicago	ÖZDEMİR Taha Reşid,alan murat,Sancı Muzaffer,KOÇ Altuğ Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. (2019): 37 - 42.
MLA	ÖZDEMİR Taha Reşid,alan murat,Sancı Muzaffer,KOÇ Altuğ Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. , 2019, ss.37 - 42.
AMA	ÖZDEMİR T,alan m,Sancı M,KOÇ A Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. . 2019; 37 - 42.
Vancouver	ÖZDEMİR T,alan m,Sancı M,KOÇ A Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. . 2019; 37 - 42.
IEEE	ÖZDEMİR T,alan m,Sancı M,KOÇ A "Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age." , ss.37 - 42, 2019.
ISNAD	ÖZDEMİR, Taha Reşid vd. "Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age". (2019), 37-42.

APA	ÖZDEMİR T, alan m, Sancı M, KOÇ A (2019). Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. Balkan Medical Journal, 36(1), 37 - 42.
Chicago	ÖZDEMİR Taha Reşid,alan murat,Sancı Muzaffer,KOÇ Altuğ Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. Balkan Medical Journal 36, no.1 (2019): 37 - 42.
MLA	ÖZDEMİR Taha Reşid,alan murat,Sancı Muzaffer,KOÇ Altuğ Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. Balkan Medical Journal, vol.36, no.1, 2019, ss.37 - 42.
AMA	ÖZDEMİR T,alan m,Sancı M,KOÇ A Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. Balkan Medical Journal. 2019; 36(1): 37 - 42.
Vancouver	ÖZDEMİR T,alan m,Sancı M,KOÇ A Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age. Balkan Medical Journal. 2019; 36(1): 37 - 42.
IEEE	ÖZDEMİR T,alan m,Sancı M,KOÇ A "Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age." Balkan Medical Journal, 36, ss.37 - 42, 2019.
ISNAD	ÖZDEMİR, Taha Reşid vd. "Targeted Next-Generation Sequencing of MLH1, MSH2 , and MSH6 Genes in Patients with Endometrial Carcinoma under 50 Years of Age". Balkan Medical Journal 36/1 (2019), 37-42.